Gene therapies are breaking new ground in treating diseases, with viral vectors emerging as a potent way to deliver them. To expand patient access and treat more disorders, manufacturers must overcome unique challenges that can impact the quality, scalability, and cost-effectiveness of the final product.
Learn how a collaboration between Cytiva and Rentschler Biopharma, enables the production of viral vectors in an efficient and flexible manner.
Cytiva brings CDMOs both efficiency and flexibility in their operations. The ultimate goal? Improving lives on a global scale.
